Entera Bio Ltd.
ENTX evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for ENTX—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · ENTX
Entera Bio Ltd. is a clinical-stage biopharmaceutical company developing orally delivered peptide therapies for osteoporosis, hypoparathyroidism, and metabolic disorders, with a lead candidate (EB613) entering a Phase 3 registrational program.
Key risk: No approved products or revenue
BioSniper Score
Based on 5 of 6 signals
Financial data as of Jun 30, 2026.
Tracking 4 pipeline candidates · 1 clinical trial for Entera Bio Ltd..
Entera Bio Ltd. is a clinical-stage biopharmaceutical company developing orally delivered peptide therapies for osteoporosis, hypoparathyroidism, and metabolic disorders, with a lead candidate (EB613) entering a Phase 3 registrational program.
- Lead product candidate EB613 (oral PTH(1-34)) is advancing toward a Phase 3 registrational program for osteoporosis [sec_mda · as of 2026-08-07].
- Cash, cash equivalents and restricted cash were $18.4M as of June 30, 2026, with an additional $10.0M raised in a July 2026 private placement, extending the cash runway into 2030 [sec_mda · as of 2026-08-07].
- Accumulated deficit was $136.2M as of June 30, 2026, reflecting ongoing R&D investment and no approved products [sec_mda · as of 2026-08-07].
- Collaboration with OPKO Health covers EB612 (LA-PTH for hypoparathyroidism) and EB618 (OXM for metabolic disorders), with $7.1M of cash designated for those activities [sec_mda · as of 2026-08-07].
What works
- Cash runway extended into 2030 following the July 2026 private placement, providing capital to execute the Phase 3 registrational program for EB613 [sec_mda · as of 2026-08-07].
- Oral peptide delivery platform could offer a differentiated, patient-friendly alternative to injectable therapies in large markets such as osteoporosis [sec_mda · as of 2026-08-07].
- Collaboration with OPKO provides co-development resources and shared expertise for EB612 and EB618 programs [sec_mda · as of 2026-08-07].
What to weigh
- No approved products or revenue; the company has incurred significant operating losses and negative cash flows from operations [sec_mda · as of 2026-08-07].
- Accumulated deficit of $136.2M as of June 30, 2026, with operating losses expected to increase as the Phase 3 program for EB613 advances [sec_mda · as of 2026-08-07].
- Clinical development is inherently uncertain; positive early-stage results may not be predictive of later-stage or registrational trial outcomes [sec · filed 2026-08-21].
- Dependence on warrant exercises for additional capital; there is no assurance that holders will exercise the outstanding warrants [sec_mda · as of 2026-08-07].
From the filings
Quoted directly from source documents.
Cash runway into 2030
“we believe that our existing cash resources, which includes the net proceeds from the July 2026 Private Placement, will be sufficient to fund our planned operations into 2030.”
SEC MD&A · August 7, 2026
Accumulated deficit
“As of June 30, 2026, we had an accumulated deficit of $136.2 million.”
SEC MD&A · August 7, 2026
Phase 3 registrational program for EB613
“advance our planned Phase 3 registrational program for EB613”
SEC MD&A · August 7, 2026
Cash designated for OPKO collaboration
“$7.1 million has been designated to fund collaboration activities with OPKO under the A&R Collaboration Agreement.”
SEC MD&A · August 7, 2026
Risks & what to watch (4)›
Key risks
- No approved products or revenue — Entera has no approved products and has generated no revenue from product sales; its ability to generate future revenue depends on successful development and regulatory approval [sec_mda · as of 2026-08-07].
- Clinical trial uncertainty — Positive early-stage results may not be predictive of later-stage or registrational trial outcomes, and the scope, cost, and timing of trials are inherently unpredictable [sec · filed 2026-08-21].
- Significant accumulated deficit — Accumulated deficit of $136.2M as of June 30, 2026, with operating losses expected to increase as the Phase 3 program for EB613 advances [sec_mda · as of 2026-08-07].
- Dependence on warrant exercises — Additional proceeds of ~$22.3M could be received if all outstanding warrants are exercised, but there is no assurance that holders will exercise them [sec_mda · as of 2026-08-07].
What to watch
- Initiation and enrollment progress of the Phase 3 registrational program for EB613 in osteoporosis [sec_mda · as of 2026-08-07].
- Updates on the EB612 (LA-PTH) and EB618 (OXM) programs under the OPKO collaboration [sec_mda · as of 2026-08-07].
- Cash burn rate and any future capital raises, including potential exercise of outstanding warrants [sec_mda · as of 2026-08-07].
- Regulatory interactions and any clinical data readouts from ongoing or planned trials [sec_mda · as of 2026-08-07].
Sources: Catalysts · SEC filings · SEC MD&A · Generated August 27, 2026 · How we verify sources →
Run Entera Bio Ltd. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Entera Bio Ltd. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 5 of 6 signals · derived from public data
16.1 months
D/E 1.68 · 0% dilution
Lead: Phase 3
4 candidates
No upcoming catalysts tracked
2 buys · 0 sells (180d)
Runway
Pipeline
Regulatory
Financials
Short Interest
as of Apr 28, 2026- % of float
- 0.4%
- Days to cover
- 1.1
- Shares short
- 192,781
- Daily short volume (Jun 9, 2026)
- 32.2%
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
ENTX short interestGovernance
Frequently asked questions
What is the AI investment thesis for Entera Bio Ltd.?
Entera Bio Ltd. is a clinical-stage biopharmaceutical company developing orally delivered peptide therapies for osteoporosis, hypoparathyroidism, and metabolic disorders, with a lead candidate (EB613) entering a Phase 3 registrational program.
What is Entera Bio Ltd.'s lead drug candidate?
Entera Bio Ltd.'s most advanced tracked candidate is eb612 (Phase 2) for Hypoparathyroidism.
Who is the CEO of Entera Bio Ltd.?
Ms. Miranda J. Toledano M.B.A. is the chief executive officer of Entera Bio Ltd. (ENTX).
Where is Entera Bio Ltd. headquartered?
Entera Bio Ltd. (ENTX) is headquartered in Jerusalem, Israel.
What therapeutic areas does Entera Bio Ltd. focus on?
Entera Bio Ltd. develops therapies across Oncology, Metabolic, Dermatology, Musculoskeletal, Gastroenterology, Endocrinology, Reproductive.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.